


The listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently Amended) ~~The use of a~~ A compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, ~~in the preparation of a composition for inhibition of HSP90 activity:~~



wherein

R<sub>1</sub> is a group of formula (IA):



wherein in any compatible combination

Ar<sup>1</sup> is an optionally substituted aryl or heteroaryl radical,

Alk<sup>1</sup> and Alk<sup>2</sup> are optionally substituted divalent C<sub>1</sub>-C<sub>6</sub> alkylene or C<sub>2</sub>-C<sub>6</sub> alkenylene radicals,

p, r and s are independently 0 or 1,

Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO<sub>2</sub>-, -C(=O)O-, -C(=O)NR<sup>A</sup>-, -C(=S)NR<sup>A</sup>-, -SO<sub>2</sub>NR<sup>A</sup>-, -NR<sup>A</sup>C(=O)-, -NR<sup>A</sup>SO<sub>2</sub>- or -NR<sup>A</sup>- wherein R<sup>A</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, and

Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical;

R<sub>2</sub> is (i) a group of formula (IA) as defined in relation to R<sub>1</sub>;

(ii) a carboxamide radical; or


(iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is

optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula  $-(\text{Alk}^1)_p-(\text{Z})_r-(\text{Alk}^2)-\text{Q}$  wherein Q,  $\text{Alk}^1$ ,  $\text{Alk}^2$ , Z, p, r and s are as defined above in relation to group (IA); and

$\text{R}_3$  is hydrogen, or methyl, ethyl, n- or iso-propyl any of which being optionally substituted by hydroxy;


X is  $-\text{OR}_4$  or  $-\text{NR}_4\text{R}_5$  wherein  $\text{R}_4$  and  $\text{R}_5$  independently represent hydrogen or optionally substituted  $\text{C}_1\text{-C}_6$  alkyl, or  $\text{R}_4$  and  $\text{R}_5$  taken together with the nitrogen to which they are attached form an optionally substituted nitrogen-containing ring having 5-8 ring atoms.

2. (Currently Amended) The ~~use compound~~ as claimed in claim 1 wherein in the compound of formula (I),  $\text{R}_1$  has formula (IB):



wherein  $\text{R}_6$  is chloro, bromo,  $\text{C}_1\text{-C}_6$  alkyl, or cyano.

3. (Currently Amended) The ~~use compound~~ as claimed in claim 1 wherein in the compound of formula (I)  $\text{R}_1$  has formula (IC):



wherein  $\text{Alk}^1$ ,  $\text{Alk}^2$ , p, r, s, Z and Q are as defined in claim 1 in relation to formula (IA), and R represents one or more optional substituents.

4. (Currently Amended) The ~~use~~compound as claimed in claim 2 wherein R is -OH in the 4- position of the phenyl ring and the  $-(\text{Alk}^1)_p-(\text{Z})_r-(\text{Alk}^2)_s-\text{Q}$  substituent is in the 5- position of the phenyl ring.
5. (Currently Amended) The ~~use~~compound as claimed in claim 4 wherein r is 0, and Q is hydrogen or optionally substituted phenyl.
6. (Currently Amended) The ~~use~~compound as claimed in claim 5 wherein s is 0, p is 1 and  $\text{Alk}^1$  is a nonsubstituted divalent  $\text{C}_1\text{-C}_6$  alkylene or  $\text{C}_2\text{-C}_6$  alkenylene radical.
7. (Currently Amended) The ~~use~~compound as claimed in claim 5 wherein  $\text{Alk}^1$  is  $-\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2-$ , or  $-\text{CH}=\text{CH}-$ .
8. (Currently Amended) The ~~use~~compound as claimed in claim 4 wherein p, r and s are each 0.
9. (Currently Amended) The ~~use~~compound as claimed in ~~any of the preceding claims~~ claim 1 wherein  $\text{R}_2$  is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl, optionally substituted by one or more of methoxy, ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, or trifluoromethyl.
10. (Currently Amended) The ~~use~~compound as claimed in ~~any of claims 1 to 8~~ claim 1 wherein  $\text{R}_2$  is optionally substituted phenyl.
11. (Currently Amended) The ~~use~~compound as claimed in ~~any of claims 1 to 8~~ claim 1 wherein  $\text{R}_2$  is phenyl substituted in the 4 position by (i)  $\text{C}_1\text{-C}_6$  alkoxy such as methoxy or ethoxy, fluoro, chloro, bromo, morpholinomethyl, piperazino, N-methylpiperazino, or piperidino, (ii) optionally substituted  $\text{C}_1\text{-C}_6$  alkyl, eg optionally substituted methyl, ethyl, n-propyl or iso-propyl (iii) optionally substituted morpholino  $\text{C}_1\text{-C}_6$  alkyl-, thiomorpholino  $\text{C}_1\text{-C}_6$  alkyl-, piperazino  $\text{C}_1\text{-C}_6$  alkyl-, methyl piperazino  $\text{C}_1\text{-C}_6$  alkyl-, or diethylamino (iv)  $-\text{NH}_2$ ,  $-\text{NHR}^A$ ,  $-\text{NR}^A\text{R}^B$ ,  $-\text{NHCOR}^A$ ,  $-\text{NHCOOR}^A$ ,  $\text{NR}^B\text{COOR}^A$ ,  $-\text{NHSO}_2\text{OR}^A$ ,  $-\text{NR}^B\text{SO}_2\text{OR}^A$ ,

-NHCONH<sub>2</sub>, -NR<sup>A</sup>CONH<sub>2</sub>, NHCONHR<sup>B</sup>, -NR<sup>A</sup>CONHR<sup>B</sup>, -NHCONR<sup>A</sup>R<sup>B</sup>, or -NR<sup>A</sup>CONR<sup>A</sup>R<sup>B</sup> wherein R<sup>A</sup> and R<sup>B</sup> are independently a (C<sub>1</sub>-C<sub>6</sub>) alkyl group or (v) optionally substituted piperadino, piperazino, morpholino or thiomorpholino.

12. (Currently Amended) The ~~use compound~~ as claimed in ~~any of claims 1 to 8~~ claim 1 wherein R<sub>2</sub> is a carboxamide radical of formula -CONR<sup>B</sup>(Alk)<sub>n</sub>R<sup>A</sup> wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1 ,

R<sup>B</sup> is hydrogen or a C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>2</sub>-C<sub>6</sub> alkenyl group,

R<sup>A</sup> is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or R<sup>A</sup> and R<sup>B</sup> taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

13. (Currently Amended) The ~~use compound~~ as claimed claim 12 wherein

Alk is an optionally substituted -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH=CH-, or -CH<sub>2</sub>CCCH<sub>2</sub>- radical.

n is 0 or 1,

R<sup>B</sup> is hydrogen, methyl, ethyl, n- or iso-propyl, or allyl,

R<sup>A</sup> is hydroxy, hydroxy and/or chloro-substituted phenyl, 3,4 methylenedioxyphenyl, pyridyl, furyl, thienyl, N-piperazinyl, or N-morpholinyl,

or R<sup>A</sup> and R<sup>B</sup> taken together with the nitrogen to which they are attached form a morpholino, piperidinyl, piperazinyl or N-phenylpiperazinyl ring.

14. (Currently Amended) The ~~use~~compound as claimed in claim 12 wherein n is 0, R<sup>B</sup> is hydrogen and R<sup>A</sup> is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.

15. (Currently Amended) The ~~use~~compound as claimed in ~~any of the preceding claims~~ claim 1 wherein R<sub>3</sub> is hydrogen.

16. (Currently Amended) The ~~use~~compound as claimed in ~~any of claims 1 to 14~~ claim 1 wherein R<sub>3</sub> is other than hydrogen and the stereochemical configuration at the carbon centre to which it is attached is that of a D amino acid.

17. (Currently Amended) The ~~use~~compound as claimed in ~~any of the preceding claims~~ claim 1 wherein X is -OR<sub>4</sub> or -NHR<sub>4</sub> wherein R<sub>4</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted by hydroxy, or a primary- secondary, tertiary- or cyclic-amino group

18. (Currently Amended) The ~~use~~compound as claimed in ~~any of the preceding claims~~ claim 1 wherein X is -NR<sub>4</sub>R<sub>5</sub> wherein R<sub>4</sub> and R<sub>5</sub> taken together with the nitrogen to which they are attached form a morpholino, piperidinyl or piperazinyl ring, the latter being optionally substituted by C<sub>1</sub>-C<sub>6</sub> alkyl on the second nitrogen.

19. (Currently Amended) A method of treatment of diseases or conditions mediated by excessive or inappropriate HSP90 activity in mammals which method comprises administering to the mammal an amount of a compound of formula (I) as defined in ~~any of claims 1 to 15~~ claim 1, or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.




20. (Currently Amended) The ~~use as claimed in any of claims 1 to 18~~ or a method as claimed claim 16 for immunosuppression or the treatment of cancer; viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-






related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's and Alzheimer's disease.





21. (Canceled)

22. (Canceled)


23. (Currently Amended) A compound ~~whose structure is set forth in any of the Examples herein,~~











---

or a salt, solvate or hydrate thereof.

24. (Currently Amended) A pharmaceutical or veterinary composition comprising a compound as defined in ~~claim 22 or claim 23~~ claim 1, together with a pharmaceutically or veterinarily acceptable carrier.